Organovo Holdings Files 10-K/A Amendment

TL;DR

Organovo Holdings filed an amendment to its 2024 10-K, check for updates.

AI Summary

Organovo Holdings, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. The filing, dated July 26, 2024, provides updated information for the company, which is involved in biological products. Organovo Holdings, Inc. is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This amendment to the annual report provides updated financial and operational information for Organovo Holdings, Inc., which is crucial for investors and stakeholders to assess the company's current status.

Risk Assessment

Risk Level: low — This filing is an amendment to an annual report and does not introduce new material risks.

Key Numbers

• 001-35996 — SEC File Number (Identifies the company's filings with the SEC.)
• 27-1488943 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• ORGANOVO HOLDINGS, INC. (company) — Registrant
• March 31, 2024 (date) — Fiscal Year End
• July 26, 2024 (date) — Filing Date
• Delaware (location) — State of Incorporation
• San Diego, CA (location) — Principal Executive Offices
• 858-224-1000 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ONVO The Nasdaq Capital M
• $10,340,301 — ant’s second fiscal quarter, was $10,340,301. For purposes of this computation only,

Filing Documents

• onvo_10k-a_2024_0331.htm (10-K/A) — 648KB
• onvo-ex31_3.htm (EX-31.3) — 6KB
• onvo-ex31_4.htm (EX-31.4) — 7KB
• 0000950170-24-086880.txt ( ) — 663KB

Executive Compensation

Executive Compensation 5 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 13 Item 13. Certain Relationships and Related Transactions, and Director Independence 15 Item 14. Principal Accountant Fees and Services 17 PART IV 19 Item 15. Exhibits and Financial Statement Schedules 19 PART III

Directors, Executive Off icers and Corporate Governance

Item 10. Directors, Executive Off icers and Corporate Governance. Board of Directors Information Our Board of Directors (Board) is comprised of six directors. Our Board is divided into three classes, with one class standing for election each year for a three-year term. There are currently two Class I directors, two Class II directors, and two Class III directors. In addition to the information set forth below regarding our directors and the skills that led our Board to conclude that these individuals should serve as directors, we also believe that all of our directors have a reputation for integrity, honesty and adherence to the highest ethical standards. We believe they each have demonstrated business acumen and an ability to exercise sound judgment, as well as a commitment of service to our Company and to their Board duties. Information About Our Directors The following sets forth information regarding the business experience of our current directors: Name Age (1) Position(s) Director Class Keith Murphy 52 Director and Executive Chairman Class III Adam Stern 60 Director Class III Douglas Jay Cohen 53 Lead Independent Director Class II David Gobel 71 Director Class II Alison Tjosvold Milhous 45 Director Class I Vaidehi Joshi 38 Director and Director of Discovery Biology Class I __________________ (1) As of July 25, 2024. Class I Directors Continuing in Office until the 2024 Annual Meeting of Stockholders Alison Tjosvold Milhous, Director , has served on our Board since September 2020. She has 20 years of audit and technical accounting experience and is a certified public accountant. She is currently the Vice President of Accounting at Erasca, Inc., a clinical-stage precision oncology company. Prior to joining Erasca, she was an independent consultant assisting public and private companies with accounting and reporting needs primarily within the life sciences and technology industries. Ms. Mil

Executive Compensation

Item 11. Executive Compensation. The following discussion is designed to provide our stockholders with an understanding of our compensation philosophy and objectives as well as an overview of the analysis that our Compensation Committee performed in setting the compensation of our executive officers for Fiscal 2024 (i.e., the period from April 1, 2023 to March 31, 2024). This discussion summarizes the Compensation Committee’s determination of how and why, in addition to what, compensation actions were taken for our named executive officers, as follows: • Keith Murphy, our Executive Chairman and Principal Executive Officer; • Thomas Hess, our Chief Financial Officer; • Thomas Jurgensen, our former General Counsel and Corporate Secretary (1) ; and • Jeffrey Miner, our former Chief Scientific Officer (2) . (1) Mr. Jurgensen’s employment with the Company was terminated as of August 25, 2023 in connection with Company’s reduction in force announced on August 18, 2023. (2) Dr. Miner’s employment with the Company was terminated as of August 25, 2023 in connection with Company’s reduction in force announced on August 18, 2023. Other than Mr. Murphy, Mr. Hess was the only executive officer serving at the end of Fiscal 2024. These four individuals are collectively referred to in this Annual Report as our “named executive officers”. Recent “Say-on-Pay” Votes Our recent stockholder advisory votes, commonly referred to as a “Say-on-Pay” vote, to approve the compensation of our named executive officers for Fiscal 2023 (i.e., the period from April 1, 2022 to March 31, 2023) was approved by our stockholders, with approximately 85% of stockholder votes cast in favor of the proposal. During Fiscal 2024, our Executive Chairman, former General Counsel, and Chief Financial Officer maintained significant stockholder engagement efforts to monitor how our investo

View Full Filing

View this 10-K/A filing on SEC EDGAR